News | Cath Lab | September 11, 2017

Systolic Blood Pressure at Time of STEMI PCI May Predict In-Hospital Mortality

Systolic Blood Pressure at Time of STEMI PCI May Predict In-Hospital Mortality

September 11, 2017 — Researchers have led a retrospective single-center study examining simple hemodynamic parameters obtained at the time of cardiac catheterization to predict in-hospital mortality following ST-elevation myocardial infarction (STEMI). Current 30-day mortality rates for primary percutaneous coronary intervention (PCI) patients with STEMI range from 2.5 to 10 percent, and 10.5 to 24 percent of those patients require mechanical hemodynamic support. The project examines the prognostic utility of an index based on systolic blood pressure (SBP) and left-ventricular end-diastolic blood pressure (LVEDP) ratio measured at the time of emergency primary percutaneous coronary intervention (PPCI). The entire study is outlined in the Editor’s Choice article of the September 2017 issue of Catheterization and Cardiovascular Interventions

The single-center study evaluated adult patients (≥ 18 years) with STEMI undergoing PPCI from April 11, 2007, to December 12, 2011. The final study included 219 patients with a mean age of 60 ±14 years. Patients’ LVEDP, SBP, and aortic diastolic blood pressure were obtained after successful revascularization and compared to major mortality risk scores.

“Our results are the first to demonstrate that the ratio of SBP/LVEDP when measured at the time of PPCI is a useful predictor of in-hospital mortality and 30-day mortality for patients experiencing STEMI,” said George Stouffer III, M.D., FSCAI, division chief of cardiology at the University of North Carolina Chapel Hill Hospitals Heart and Vascular Center at Meadowmont. “Invasive hemodynamic measurements at the time of PPCI have the theoretical advantage of better reflecting both left ventricular loading conditions and afterload than do non-invasive assessments. Our results show that this simple index predicted mortality at a level consistent with more commonly used, and more cumbersome prognostic indices, such as the Thrombolysis in Myocardial Infarction (TIMI) score, the Global Registry of Acute Coronary Events (GRACE) score and Killip Class.”

The SBP/LVEDP ratio ≤ 4 was associated with a likelihood ratio of 4.7 for in-hospital death, 5.8 for intra-aortic balloon pump (IABP) usage and 5.9 for the combined IABP usage or in-hospital death. “The performance characteristics of this ratio at high levels provide rapid and accurate identification of patients at the time of PPCI for STEMI who are low risk for death or need for IABP,” Stouffer added. A total of 20 (9.1%) patients died in-hospital and 34 (15.5%) required an IABP. The area under curve (AUC) for SBP/LVEDP ratio for in-hospital mortality (0.69) was more predictive than LVEDP (0.61, P = 0.04) or pulse pressure (0.55, P = 0.02) but similar to Shock Index and Modified Shock Index.

“SBP/LVEDP is a rapidly determined ratio that can provide important prognostic information at the time of PPCI,” said Michael Yeung, MD, assistant professor of medicine, division of cardiology at the University of North Carolina Chapel Hill Hospitals. “The pressure values are readily obtained during PPCI and identify a population at high risk for mortality. This presents an opportunity to identify patients who might benefit from more aggressive hemodynamic support while in the Cardiac Catheterization Laboratory.” 

The authors of “Ratio of systolic blood pressure to left ventricular end-diastolic pressure at the time of primary percutaneous coronary intervention predicts in-hospital mortality in patients with ST-elevation myocardial infarction” include Michael Sola, M.D.; Kiran Venkatesh, M.D.; Melissa Caughey, Ph.D.; Robert Rayson, M.D.; Xuming Dai, M.D.,FSCAI; George Stouffer III, M.D., FSCAI; and Michael Yeung, M.D. 

For more information: www.scai.org/CCI


Related Content

News | Cath Lab

March 25, 2026 — Royal Philips has launched its intuitive interventional guidance platform, IntraSight Plus, which is ...

Home March 26, 2026
Home
Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
Subscribe Now